Category: Deep Dive The Future of Oncology

  • GSK’s John Fleming on rethinking oncology from the ground up

    What if we could look at cancer treatment from a completely fresh perspective? This is the philosophy GSK’s UK country medical head for oncology, John Fleming, wants to bring to the company as it rethinks its approach to cancer. Fleming joined Novartis in 2015, when GSK divested its oncology portfolio to the Swiss firm. It […]

  • Commercialising innovative new medicines

    As pharmaceutical ingenuity hits new heights, ensuring that patients gain access to innovative medicines requires a unique combination of evidence generation and communication Working with all stakeholders to generate evidence that communicates value, from early phase development to launch and reimbursement, is essential in therapy areas including oncology. These are challenging times for the pharmaceutical […]

  • How to increase haematologists’ and oncologists’ confidence with new treatments

    A new whitepaper from Medscape highlights the difficulties haematologists and oncologists face in keeping up with rapid developments in treatment. We speak to the company’s Katie Lucero and Victoria Harvey-Jones to find out how independent medical education is changing to help HCPs increase their confidence in treating cancer patients. It’s an exciting time to be […]

  • Clinical decision support tools will help oncologists manage complexity

    Making treatment decisions is a tough choice for oncologists: a therapy might save or significantly extend one patient’s life but not deliver the desired outcome for another patient. Reaching this decision involves weighing a variety of data – from clinical trials to the patient’s medical background – and with the advent of more personalised oncology, […]